Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Shareholders for Regeneron Pharmaceuticals, Inc., held on June 12, 2026. The filing details the outcomes of shareholder votes on director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Proposal 1: Election of Directors
Five Class II director nominees were elected to serve until the 2027 Annual Meeting. Notable voting statistics include:
- Joseph L. Goldstein, M.D.: Received 72,398,297 votes "For" and 30,904,254 votes "Against".
- Christine A. Poon: Received 79,409,070 votes "For" and 24,004,880 votes "Against".
- David P. Schenkein, M.D.: Received 99,241,219 votes "For" and 4,180,107 votes "Against".
- Craig B. Thompson, M.D.: Received 81,933,651 votes "For" and 21,378,567 votes "Against".
- Huda Y. Zoghbi, M.D.: Received 100,665,234 votes "For" and 2,698,397 votes "Against".
- Broker Non-Votes: 5,543,411 votes were recorded as broker non-votes for all nominees.
Proposal 2: Ratification of Auditor
Shareholders approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 102,503,788
- Against: 6,443,958
- Abstain: 68,819
Proposal 3: Advisory Vote on Executive Compensation
The advisory resolution to approve the compensation of named executive officers was approved.
- For: 96,469,374
- Against: 6,898,268
- Abstain: 105,512
- Broker Non-Votes: 5,543,411
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote tallies.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Against" votes (approx. 30.9M) cast for director nominee Joseph L. Goldstein, M.D., compared to lower opposition for other nominees.
- Confirm the total number of shares outstanding and voting power to contextualize the 5.5M broker non-votes.
- Review the definitive proxy statement (Schedule 14A) filed on April 24, 2026, for details on the executive compensation package approved in Proposal 3.
- Check subsequent filings for the official appointment of the newly elected directors and any changes to the Board composition.